Rabbit anti-Human, Mouse RelB Polyclonal Antibody | anti-RelB antibody

RelB (Phospho-Ser552) Antibody

Cat. Num. AAA9503155

• Gene Names: RELB; IREL; I-REL; IMD53; REL-B
• Reactivity: Human, Mouse
• Applications: Western Blot, Immunohistochemistry, ELISA
• Purity: Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
• Synonyms: RelB; Polyclonal Antibody; RelB (Phospho-Ser552) Antibody; anti-RelB antibody

• Host: Rabbit
• Reactivity: Human, Mouse
• Clonality: Polyclonal
• Specificity: RelB (Phospho-Ser552) Antibody detects endogenous levels of RelB only when phosphorylated at Ser552.
• Purity/Purification: Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
• Form/Format: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Concentration: 1 mg/ml (varies by lot)
• Sequence Length: 579

• Applicable Applications for anti-RelB antibody: Western Blot (WB), Immunohistochemistry (IHC), ELISA (EIA)
• Application Notes: WB: 1:500~1:1000; IHC: 1:50~1:100; ELISA: 1:20000
• Target Modification: Phospho
• Modification Sites: H:S573; M:S552
• Immunogen: The antiserum was produced against synthesized peptide derived from human RelB around the phosphorylation site of Ser552.
• Immunogen Range: 530-579
• Preparation and Storage: Stable at -20 degree C for at least 1 year.

Immunohistochemistry (IHC)

(Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using RelB (Phospho-Ser552) Antibody. The picture on the right is blocked with the phospho peptide.)

Western Blot (WB)

(Western blot analysis of lysates from LOVO cells and RAW264.7 cells, using RelB (Phospho-Ser552) Antibody. The lane on the right is blocked with the phospho peptide.)

NCBI and Uniprot Product Information

• NCBI GI #: 35493878
• NCBI GeneID: 5971
• NCBI Accession #: NP_006500.2
• NCBI GenBank Nucleotide #: NM_006509.3
• UniProt Accession #: Q01201; Q6GTX7; Q9UEI7
• Molecular Weight: 62 kDa
• NCBI Official Full Name: transcription factor RelB
• NCBI Official Synonym Full Names: RELB proto-oncogene, NF-kB subunit
• NCBI Official Symbol: RELB
• NCBI Official Synonym Symbols: IREL; I-REL; IMD53; REL-B
• NCBI Protein Information: transcription factor RelB
• UniProt Protein Name: Transcription factor RelB
• Protein Family: Antitoxin
• UniProt Gene Name: RELB

Uniprot Description

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. Is required for both T and B lymphocyte maturation and function (PubMed:26385063).